Effective Lipid Emulsion Treatment of a Venlafaxine Intoxication Case with Status Epilepticus
PDF
Cite
Share
Request
Case Report
P: 213-216
December 2020

Effective Lipid Emulsion Treatment of a Venlafaxine Intoxication Case with Status Epilepticus

J Turk Soc Intens Care 2020;18(4):213-216
1. Sağlık Bilimleri Üniversitesi Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Yoğun Bakım Kliniği, Çocuk Yoğun Bakım Ünitesi Bölümü, İstanbul, Türkiye
2. Sağlık Bilimleri Üniversitesi, Bakırköy Dr. Sadi Konuk Sağlık Eğitim ve Araştırma Hastanesi, Çocuk Yoğun Bakım Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 23.10.2018
Accepted Date: 13.05.2020
Publish Date: 25.12.2020
PDF
Cite
Share
Request

ABSTRACT

Venlafaxine is a serotonergic and noradrenergic antidepressant. It shares serotonergic adverse effects with selective serotonin reuptake inhibitor (SSRI) antidepressants and causes noradrenergic adverse effects in particular cardiovascular disorders. However, it does not demonstrate advantages over SSRIs regarding efficacy. Most patients with a venlafaxine overdose develop only mild symptoms. Severe toxicity has been reported for venlafaxine, with the most common symptoms being central nervous system depression, serotonin toxicity, seizure or cardiac conduction abnormalities. We present a case of venlafaxine intoxication complicated by a late increase in creatine kinase (CK) level, seizures and cardiac toxicity. As reported in the literature, venlafaxine overdose can be fatal and can lead to cardiac toxicity and death. Patients may benefit from lipid emulsion-mediated therapeutic plasma exchange for the treatment of the lethal effects of venlafaxine intoxication. A 14-year-old patient with status epilepticus, long QTc interval and elevated CK level after venlafaxine overdose was successfully treated with lipid emulsion-mediated therapeutic plasma exchange.

Keywords: Venlafaxine intoxication, lipid emulsion treatment, status epilepticus, therapeutic plasma exchange, long QTc interval

References

1
Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-61.
2
Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000;355:911-18.
3
Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. Clin Ther 2003;25:2138-54.
4
Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006;14:796-802.
5
Howell C, Wilson AD, Waring WS. Cardiovasculer toxicity due to venlafaxine poisoning in adults: a review of 235 cobsecutive cases. Br J Clin Pharmocol 2007;64:192-7.
6
Oliver JJ, Kelly C, Jarvie D, Denieul S, Bateman DN. Venlafaxine poisoning complicated by a late rise in creatine kinase: two case reports. Hum Exp Toxicol 2002;21:463-6.
7
Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369-74.
8
Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol 2008;4:18-20.
9
Gosselin S, Hoegberg LCG, Hoffman RS, Graudins A, Stork CM, Thomas SHL, et al. Evidencebased recommendations on the use of intravenous lipid emulsion therapy in poisoning, Clin Toxicol (Phila) 2016;54:899-923.
10
Avcil M, Kapçı M, Yavaşoğlu I, Kantekin B, Akpek M. Simultaneous use of intravenous lipid emulsion and plasma exchange therapies in multiple drug toxicity. Med Princ Pract 2016;25:577-9.
2024 ©️ Galenos Publishing House